Prosonix is an innovative speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by design
Latest News
May 15, 2014
Prosonix to Present Results of Phase 2 Study of PSX1002 in COPD at ATS Meeting
Apr 15, 2014
Prosonix and Mylan Enter Into Global Licensing Agreement for Generic Versions of Inhaled...
Jan 23, 2014
Prosonix Reports Positive Top-line Results from its Phase 2 Clinical Study with PSX1002 in...
6-10 Sept 2014
Munich, Germany
19-20 Nov 2014
London, UK
Terms & Conditions
© Prosonix Ltd, 2013
The Magdalen Centre   Robert Robinson Avenue   Oxford Science Park   Oxford   OX4 4GA   United Kingdom   |   Tel: +44 (0)1865 784250   |   Email: Here